William L.  Macias net worth and biography

William Macias Biography and Net Worth

Insider of Immunovant
Presently, William L. Macias is Chief Medical Officer at Immunovant, Inc.

He is also Senior Medical Director at Lilly Research Laboratories.

In his past career he occupied the position of Chief Executive Officer at Focus Biomedical Consulting LLC, Chief Medical Officer of PROMETHERA Biosciences SA and Associate Professor at The Indiana University School of Medicine.

William L. Macias received an undergraduate degree from Marquette University and a doctorate from The Indiana University School of Medicine.

What is William L. Macias' net worth?

The estimated net worth of William L. Macias is at least $7.31 million as of January 15th, 2025. Dr. Macias owns 359,408 shares of Immunovant stock worth more than $7,306,765 as of February 15th. This net worth approximation does not reflect any other assets that Dr. Macias may own. Additionally, Dr. Macias receives a salary of $719,880.00 as Insider at Immunovant. Learn More about William L. Macias' net worth.

How old is William L. Macias?

Dr. Macias is currently 65 years old. There are 6 older executives and no younger executives at Immunovant. Learn More on William L. Macias' age.

What is William L. Macias' salary?

As the Insider of Immunovant, Inc., Dr. Macias earns $719,880.00 per year. There are 2 executives that earn more than Dr. Macias. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on William L. Macias' salary.

How do I contact William L. Macias?

The corporate mailing address for Dr. Macias and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at info@immunovant.com. Learn More on William L. Macias' contact information.

Has William L. Macias been buying or selling shares of Immunovant?

During the last quarter, William L. Macias has sold $56,786.89 in Immunovant stock. Most recently, William L. Macias sold 2,383 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $23.83, for a transaction totalling $56,786.89. Following the completion of the sale, the insider now directly owns 359,408 shares of the company's stock, valued at $8,564,692.64. Learn More on William L. Macias' trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. During the last twelve months, insiders at the sold shares 40 times. They sold a total of 241,656 shares worth more than $6,778,366.96. The most recent insider tranaction occured on January, 22nd when CTO Jay S Stout sold 2,195 shares worth more than $51,780.05. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 1/22/2025.

William L. Macias Insider Trading History at Immunovant

See Full Table

William L. Macias Buying and Selling Activity at Immunovant

This chart shows William L Macias's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$57ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $20.33
Low: $19.89
High: $20.49

50 Day Range

MA: $23.87
Low: $19.22
High: $28.94

2 Week Range

Now: $20.33
Low: $19.07
High: $39.55

Volume

1,241,001 shs

Average Volume

1,356,782 shs

Market Capitalization

$3.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65